Recent Blog Posts

View Post: Rasburicase Approved to Manage Complications of Anticancer Therapy ...
10 Nov 2009
Sanofi-aventis US announced that the US Food and Drug Administration (FDA) has granted marketing approval for rasburicase (Elitek) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, ...
View Blog: Cancer Network - http://www.cancernetwork.com/

---

View Post: FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric ...
16 Oct 2009
BRIDGEWATER NJ Oct. 16 /- Sanofi-aventis U....Today's FDA approval was based on pivotal Phase 3 trial results which ... The approval of Elitek in adult patients with cancer now provides phy...Clinical TLS was defined by changes in at ...
View Blog: Latest Medical Technology from Bio-Medicine.Org - http://www.bio-medicine.org/medicine-technology...

---

View Post: FDA Approves Elitek (rasburicase) for Management of Plasma Uric ...
19 Oct 2009 by Amit  
Sanofi-aventis US announced that the US FDA has granted marketing approval for Elitek® (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor ...
View Blog: Generic Pharmaceuticals and Patents - http://genericspatent.blogspot.com/

---

View Post: blood -- a randomized comparison between rasburicase and ...
12 Sep 2009 by Calvin and Lawrence  
anti-acidity. prevacid. our price: $0.58. prevacid (lansoprazole) decreases the amount of acid produced in the stomach. more info. zyloprim. our price: $0.51. zyloprim (allopurinol) is used to lower blood uric acid levels. more info ...
View Blog: Golf: Relaxing Sport - http://golfrelaxingsport.blogspot.com/

---

View Post: Phase 2 trial of plinabulin (NPI-2358) for the treatment of ...
23 Nov 2009
Elitek (rasburicase, from sanofi-aventis), a recombinant urate oxidase enzyme, has been approved for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are ...
View Blog: Latest articles from MPR - http://www.empr.com/

---